トレチノインの世界市場（2025年～2032年）

世界のトレチノインの市場規模は、2024年に26億4,000万米ドルに達し、2032年には62億9,000万米ドルに達すると予測され、予測期間2024年～2032年のCAGRは11.5%で成長する見込みです。

トレチノインは、ビタミンAから誘導される局所レチノイドで、にきび治療、小じわの減少、肌全体の質感の改善に効果があることから皮膚科で広く使用されています。細胞のターンオーバーを促進し、毛穴の詰まりを防ぎ、コラーゲンの生成を促進することで、ニキビとエイジングサインの両方に対する重要な治療となります。

トレチノインは、クリーム、ジェル、ソリューションなど様々な剤型があり、一般的な肌の悩みに対応する実績から、皮膚科医から処方されることが多いです。トレチノインの人気の高まりは、その利点に対する認知度の高まりと、肌の若返りのための信頼できるソリューションとしての評判によって後押しされています。

市場力学：

促進要因と抑制要因

皮膚疾患の有病率の上昇

皮膚病、特ににきびや老化の兆候の高い有病率は、トレチノイン市場の成長を大きく促進すると予想されます。トレチノインは、ニキビとシワの両方に有効であることが認められており、これらの一般的な皮膚問題に対処するための処方箋として皮膚科医の間で人気が高まっています。例えば、2023年の米国国立衛生研究所の報告によると、ニキビは青少年の70％～87％が罹患しており、社会的孤立、うつ病、自殺念慮などの重大な心理社会的問題と関連していることが多いです。このように青少年のメンタルヘルスに広く影響を与えていることから、炎症性ニキビとニキビ後の瘢痕の両方に対応できることで広く認知されているトレチノインを含む、効果的な治療に対する需要が高まっています。

特に思春期や若年成人のニキビ患者数は増加の一途をたどっており、トレチノインは最も効果的な外用治療薬の1つであることから、需要の拡大が見込まれています。細胞のターンオーバーを促進し、毛穴の詰まりを取り除き、炎症を抑えるトレチノインの能力は、ニキビを管理するための最適なソリューションであり、市場成長にさらに貢献しています。ニキビの心理的影響に対する認識が高まるにつれて、患者はトレチノインのような効果的な治療を求める傾向が強まり、世界市場におけるこの治療に対する需要の増加に拍車をかけています。

トレチノインに関連する副作用

トレチノインに関連する副作用（皮膚の炎症、発赤、剥離、日光に対する過敏性の増加など）は、トレチノイン市場の成長を妨げると予想されます。これらの副作用は、特に敏感肌の消費者にとっては、製品の使用を躊躇させる可能性があります。一般的には軽度で一時的なものではありますが、不快感によって治療が中断され、市場導入が減少する可能性があります。さらに、特に長期間の使用による潜在的な長期的影響に対する懸念は、特に新規ユーザーや皮膚に既往症のある消費者の間での普及をさらに制限する可能性があり、それによって市場全体の可能性が制限されることになります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 皮膚疾患の罹患率の上昇
  • 抑制要因
    • トレチノインに関連する副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 投与量別

• 0.025%
• 0.01%
• 0.05%
• 0.1%
• その他

第7章 用途別

• ニキビ
• 急性前骨髄球性白血病（APL）
• その他

第8章 流通チャネル別

• 院内薬局
• オンライン薬局
• 小売薬局
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Bausch Health Companies Inc.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 実績および予測の製品販売
    • 製品販売量
  • 財務概要
    • 企業収益
    • 地域別収益シェア
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Galderma
• AdvaCare Pharma
• Teva Pharmaceuticals USA, Inc.
• Wellona Pharma
• Bausch Health Companies Inc.
• Glenmark Pharmaceuticals Inc., USA
• Amber Lifesciences Pvt. Ltd.
• Viatris Inc.
• Kavyapharma
• GSK plc
  • パイプライン製品の説明
  • 製品の主要業績評価指標（KPI）
  • 主な活動
  • 市場参入のタイムライン
  • 製品普及率
  • 売上推定と予測
• Takeda Pharmaceutical Company Limited
• Poseida Therapeutics
• Regeneron Pharmaceuticals, Inc.
• Genentech, Inc.

第12章 付録

The global Tretinoin market reached US$ 2.64 billion in 2024 and is expected to reach US$ 6.29 billion by 2032, growing at a CAGR of 11.5% during the forecast period 2024-2032.

Tretinoin, a topical retinoid derived from vitamin A, is widely used in dermatology for its effectiveness in treating acne, reducing fine lines, and improving overall skin texture. It works by promoting cell turnover, preventing clogged pores, and stimulating collagen production, making it a key treatment for both acne and signs of aging.

Tretinoin is available in various formulations such as creams, gels, and solutions, tretinoin is often prescribed by dermatologists for its proven results in addressing common skin concerns. Its growing popularity is fueled by increasing awareness of its benefits and its reputation as a trusted solution for skin rejuvenation.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Dermatological Conditions

The high prevalence of dermatological conditions, particularly acne, and signs of aging, is expected to significantly drive the growth of the tretinoin market. Tretinoin, recognized for its effectiveness in treating both acne and wrinkles, is becoming an increasingly popular prescription among dermatologists for addressing these common skin issues. For instance, according to the National Institute of Health report in 2023, acne, a prevalent skin condition affects 70% to 87% of adolescents and is often linked to significant psychosocial issues such as social isolation, depression, and suicidal ideation. This widespread impact on adolescents' mental health is driving increased demand for effective treatments, including tretinoin, which is widely recognized for its ability to address both inflammatory acne and post-acne scarring.

As the number of acne cases continues to rise, especially among adolescents and young adults, the demand for tretinoin is expected to grow, as it is considered one of the most effective topical treatments available. Its ability to accelerate cell turnover, unclog pores, and reduce inflammation makes tretinoin a go-to solution for managing acne, further contributing to its market growth. As awareness of acne's psychological impact grows, patients are more likely to seek out effective therapies like tretinoin, fueling increased demand for this treatment in the global market.

Side Effects Associated with Tretinoin

The side effects associated with tretinoin, such as skin irritation, redness, peeling, and increased sensitivity to sunlight, are expected to hinder the tretinoin market's growth. These adverse reactions can deter some consumers from using the product, especially those with sensitive skin. While typically mild and temporary, the discomfort may lead to discontinuation of treatment, reducing market adoption. Additionally, concerns about potential long-term effects, especially with prolonged use, could further limit widespread use, particularly among new users or those with pre-existing skin conditions, thereby restricting the overall market potential.

Segment Analysis

The global Tretinoin market is segmented based on dosage, application, distribution channel, and region.

Type:

• 0.1% tretinoin segment is expected to dominate the global tretinoin market share

The 0.1% tretinoin segment is expected to dominate the market due to its proven effectiveness in treating moderate to severe acne and reducing signs of aging. This concentration is the most widely prescribed strength by dermatologists, offering optimal results for patients seeking powerful, fast-acting solutions. It is favored for its ability to penetrate the skin deeply and deliver noticeable improvements in skin texture and clarity. As a result, the 0.1% segment continues to hold a significant share of the market, driven by its widespread use in both medical and cosmetic dermatology treatments.

Geographical Analysis

North America is expected to hold a significant position in the global tretinoin market share

North America is expected to maintain a dominant position in the global tretinoin market due to its strong presence in dermatological clinics and high consumer demand for dermatological treatments. The U.S. leads the region, benefiting from widespread skin health awareness, easy dermatologists access, and a high adoption rate of prescription-based skincare solutions.

An increasing number of youngsters suffering from skin diseases such as acne and other related diseases is expected to increase the demand for tretinoin in the region. For instance, according to the American Academy of Dermatology Association, in the updated report, acne is the most common skin condition in the United States and affects up to 50 million Americans annually.

The presence of major pharmaceutical companies and advanced medical research also increases the availability and variety of tretinoin products. With a large, affluent consumer base seeking effective anti-aging and acne treatments, North America remains in the dominant position in the tretinoin market.

Competitive Landscape

The major global players in the tretinoin market include Bausch Health Companies Inc., Galderma, AdvaCare Pharma, Teva Pharmaceuticals USA, Inc., Wellona Pharma, Bausch Health Companies Inc., Glenmark Pharmaceuticals Inc., USA, Amber Lifesciences Pvt. Ltd., Viatris Inc. and Kavyapharma among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Tretinoin Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Dosage
• 3.2. Snippet by Application
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Dermatological Conditions
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects Associated with Tretinoin
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Dosage

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 6.1.2. Market Attractiveness Index, By Dosage
• 6.2. 0.025%*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. 0.01%
• 6.4. 0.05%
• 6.5. 0.1%
• 6.6. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Acne*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Acute Promyelocytic Leukemia (APL)
• 7.4. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospitals Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

• 11.1. Bausch Health Companies Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Galderma
• 11.3. AdvaCare Pharma
• 11.4. Teva Pharmaceuticals USA, Inc.
• 11.5. Wellona Pharma
• 11.6. Bausch Health Companies Inc.
• 11.7. Glenmark Pharmaceuticals Inc., USA
• 11.8. Amber Lifesciences Pvt. Ltd.
• 11.9. Viatris Inc.
• 11.10. Kavyapharma
• Similar data will be provided for each market player.

Emerging Market Players

• 11.11. GSK plc*
  • 11.11.1. Pipeline Products Description
  • 11.11.2. Product Key Performance Indicators (KPIs)
  • 11.11.3. Key Activities
  • 11.11.4. Market Entry Timelines
  • 11.11.5. Product Penetration Rate
  • 11.11.6. Sales Estimation and Projections
• 11.12. Takeda Pharmaceutical Company Limited
• 11.13. Poseida Therapeutics
• 11.14. Regeneron Pharmaceuticals, Inc.
• 11.15. Genentech, Inc.
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services